



Y-1595

Production of ***Active Pharma Ingredients (API)***

(Amoxicillin Trihydrate,
Azithromycin & Paracetamol)
Investment Opportunities in
Pharmaceutical Industry



Introduction

An active ingredient (AI) is that the ingredient in an exceedingly pharmaceutical drug that's biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active i.e. bulk medicine are utilized in medicine, and therefore the term active substance could also be used for natural products. Thus, depending on the drug's administered dosage, the reactions and results differ. Certain drugs are comprised of more than one kind of API.

Related Videos: - [Active Pharma Ingredients \(API\) - Global Market Estimated to Reach US\\$ 21.9 billion by 2023](#)



Amoxicillin is an antibiotic used to treat variety of bacterial infections. These include middle ear infection, strep throat, pneumonia, skin infections, and tract infections among others. It's taken orally, or less usually by injection.

Related Videos: [Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit](#)

[Active Pharmaceutical Ingredient](#) (API), is that the term used to check with the biologically active component of a drug product (e.g. tablet, capsule). Drug products are typically composed of many elements. The aforementioned API is that the primary ingredient. Alternative ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components utilized in the drug is known as formulation.

Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and bound alternative intestinal infections it also can be used for variety of sexually transmitted infections, as well as chlamydia and gonorrhea infections. At the side of alternative medications, it's going to even be used for malaria. It may be taken by mouth or intravenously with doses once per day. It is on the world Health Organization's List of Essential Medicines, the safest and most effective medicines required in a very health system. It's one in all the most usually prescribed antibiotics in children. Trim ox is on the market as a generic medication.

Azithromycin alone and in combination with different medications is currently being studied for the treatment of [coronavirus](#) wellness 2019 ([COVID-19](#)). Currently, azithromycin has been used with hydroxychloroquine to treat certain patients with COVID-19. However, there are mixed reports of effectiveness once azithromycin was used at the side of alternative medications to treat other viral respiratory infections. Azithromycin also has been used to treat bacterial infections in hospitalized patients with COVID-19. A lot of information is required before any conclusions may be made regarding the possible advantages and risks of using azithromycin either alone or together with hydroxychloroquine in patients with COVID-19.



Amoxicillin Trihydrate may be a hydrate that's the Trihydrate type of amoxicillin; a semisynthetic antibiotic, used either alone or together with potassium clavulanate (under the name Augmentin) for treatment of a variety of bacterial infections. It's a role as an antibacterial drug and an antimicrobial agent. It contains an amoxicillin.

Related Books: - [Pharmaceutical, Drugs, Proteins Technology Handbooks](#)



Manufacturing Process

The Manufacturing Process of Paracetamol is Summarized in the Following Steps:

- charge acetic acid to the reactor.
- add p-nitro phenol as a starting material and iron powder as catalyst.
- Heat to temp 80-90 °C.
- The reaction is exothermic and temp will rise to 130 °C.
- After slight cooling
- Reflux the reaction at 118°C for 3-4 hours.
- Cool to 60 °C.

- Add methanol to the reaction.
- Reflux for 1 hour.
- distill the methanol and recycle.
- Add water to the obtained cake.
- And make a solution
- Add activated carbon.
- Filter
- Dry the cake.
- Pulverize the dry cake to get the Paracetamol fine powder.



Applications:-

- Communicable Diseases
- Oncology
- Diabetes
- Cardiovascular Diseases
- Pain Management
- Respiratory Diseases
- Other Therapeutic Applications



Role of Government Towards API

The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports.

Related Videos: - **Production of Paracetamol (Acetaminophen), bulk pharmaceutical active ingredient**

On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively.

The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years.

The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk [Drug](#) Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc.

Related Videos: - [Investment Opportunities in APIs KSMs Drug Intermediates Bulk Drug Industries](#)

The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/[drug](#) intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years.

Financial incentive will be given to eligible manufacturers of identified 53 critical [bulk drugs](#) on their incremental sales over the base year (2019-20) for a period of 6 years.

Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are [chemical](#) synthesis based bulk drugs.

Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs.

The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years.

The drug industry has welcomed the incentives offered by the government to promote API units in India.

Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore.



The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years.

Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices.

Related Videos: - [Manufacturing Business Ideas in Pharmaceutical Industry](#)



Union Cabinet scheme on Promotion of Bulk Drug Parks

- The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years.
- Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years.



Details:

Promotion of Bulk Drug Parks

- Decision is to develop 3 mega Bulk Drug parks in India in partnership with States.
- Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.
- Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc.
- A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years.



Production Linked Incentive Scheme

- Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.
- Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.
- Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs.
- A sum of Rs. 6,940 crore has been approved for next 8 years.



Market Outlook

Active Pharmaceutical Ingredient Market is valued at USD 172.69 Billion in 2018 and expected to reach USD 263.80 Billion by 2025 with the CAGR of 6.24% over the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates

Drugs and over-the-counter (OTC) drugs. In 2019, the prescribed drugs segment is expected to account for the most important share of the [APIs market](#). The demand for drugs falling under this class has increased significantly in recent years because of the rising prevalence of target diseases. Additionally, the most important share of the prescription drugs segment also can be attributed to the increased focus of innovator corporations on the development of specialty drugs and affordability of health care. The implementation of significant federal reforms to improve the affordability of [healthcare](#), especially in the, us has expanded the consumption of each traditional and specialty medicine. Also, inflation has played a key role in enhancing revenue from the sales of prescription drugs, significantly specialty drugs. All these factors are collectively responsible for the large share of this phase. Based on the kind of drug, the APIs market can be classified into two segments prescribed.

Manufacturer Insights

On the basis of type of manufacturer, the API market has been segmented into merchant and captive APIs. Captive API command the most important share in 2019 because of simple availability of raw materials and intensive capitalization of major key players for the development of high-end manufacturing facilities.

API is calculable to be the fastest-growing segment over the forecast period. The segment growth is driven by factors similar to high cost of in-house manufacturing of those molecules and rising demand for biopharmaceuticals.

Related Videos: - [Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs](#)

Active Pharmaceutical Ingredient (APIs) are portions of any drugs that are biologically active in nature. The APIs have significant use in the manufacturing of effective and safe medicines. Depending on the drug's administered dosage, the reactions and results take issue according to the requirement and use for specific treatment of diseases. Sure medicine are contained of over one kind of API. medicine are chosen primarily for his or her active ingredients to treat variety of chronic and infectious diseases similar to diabetes, cancer, arthritis, bone & joint infections, pneumonia, otitis, streptococcal pharyngitis, cellulites, and tract infections. However, the standard will vary widely from one whole to a different. Medicine are chosen primarily from active ingredients within the liquid or solid form like tablet or alternative throughout.

Global Active Pharmaceutical Ingredient Market Dynamics

The key issue for growth of worldwide Active [Pharmaceutical](#) Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has up to 18.1 million new cases as well as 9.6 million deaths across the world. Because of such rise within the cases of cancer, the new drugs discovery using the Active [Pharmaceutical](#) Ingredient has become essential. Recently in line with the American [Chemical](#) Society in 2019, there has been 48 new drugs has been approved by the fad U.S. out of that 11 for new cancer treatments with the innovative molecular [pharmaceutical](#) ingredients.

However, the Active [Pharmaceutical](#) Ingredient market is hampered by would like for prime investment with huge capital demand for research and developments. Moreover rising health cautiousness among the people with technological advancement immense investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional growth can provide huge opportunity for Active [Pharmaceutical](#) Ingredient market. For instance in 2019, Raquel has been acquired by Merck & Co. for roughly around USD 2.7 billion in cash, for making cancer drug using Active [Pharmaceutical](#) Ingredient with the most recent small-molecule-focused.



Expansion of Manufacturing Facilities Creating Lucrative Opportunities for Market Growth

Majority of specialty API companies are increasing their manufacturing facilities for specialty [active pharmaceutical ingredients](#) (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active [pharmaceutical](#) ingredients (API) is one in all the most important factors among key players in the specialty active [pharmaceutical](#) ingredients (API) market.

For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand.

In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active [pharmaceutical](#) ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility.

The emergence of [COVID-19](#) has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic.



Focus on Healthcare to Drive the Active Pharmaceutical Ingredients Market

The spending on healthcare has grown at a rapid pace in recent years and it increased at a CAGR of 6.92% between the years 2003 and 2013. The healthcare spending growth was significantly higher than the population growth rate that grew at a CAGR of 1.22% for the same period. The per capita healthcare spending rose from just under US\$ 600 in 2003 to above US\$ 1000 in 2013, at an average CAGR of 5.62%. The focus on healthcare spending was observed to be a global phenomenon and this directly benefited the active pharmaceutical ingredients market.



Key Players

Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK). Sun Pharmaceutical Industries Ltd.

Machinery Photographs



JACKETED REACTOR



FILTER



STORAGE TANK



BOILER

Project at a Glance

COST OF PROJECT				MEANS OF FINANCE			
Particulars	Existing	Proposed	Total	Particulars	Existing	Proposed	Total
Land & Site Development Exp.	0.00	605.00	605.00	Capital	0.00	330.52	330.52
Buildings	0.00	134.00	134.00	Share Premium	0.00	0.00	0.00
				Other Type Share			
Plant & Machineries	0.00	174.50	174.50	Capital	0.00	0.00	0.00
Motor Vehicles	0.00	8.00	8.00	Reserves & Surplus	0.00	0.00	0.00
Office Automation Equipments	0.00	32.00	32.00	Cash Subsidy	0.00	0.00	0.00
Technical Knowhow Fees & Exp.	0.00	25.00	25.00	Internal Cash			
Franchise & Other				Accruals	0.00	0.00	0.00
Deposits	0.00	0.00	0.00	Long/Medium Term			
Preliminary& Pre-operative Exp	0.00	1.00	1.00	Borrowings	0.00	991.56	991.56
Provision for				Debentures / Bonds	0.00	0.00	0.00
Contingencies	0.00	15.25	15.25	Unsecured			
Margin Money - Working Capital	0.00	327.33	327.33	Loans/Deposits	0.00	0.00	0.00
TOTAL	0.00	1322.08	1322.08	TOTAL	0.00	1322.08	1322.08

Project at a Glance

Year	Annualised		Book Value	Debt	Divide nd	Retained Earnings		Payout	Probabl e Market Price	P/E Ratio	Yield Price/ Book Value
	EPS	CEPS	Per Share		Per Share	Per Share				No.of Times	
	`	`	`	`	`	%	`	%	`		%
1-2	8.04	9.47	18.04	24.00	0.00	100.00	8.04	0.00	8.04	1.00	0.00
2-3	10.49	11.74	28.53	18.00	0.00	100.00	10.49	0.00	10.49	1.00	0.00
3-4	13.04	14.14	41.56	12.00	0.00	100.00	13.04	0.00	13.04	1.00	0.00
4-5	15.54	16.50	57.10	6.00	0.00	100.00	15.54	0.00	15.54	1.00	0.00
5-6	17.97	18.82	75.07	0.00	0.00	100.00	17.97	0.00	17.97	1.00	0.00

Project at a Glance

Year	D. S. C. R.			Debt / Equity - Deposits Debt	Equity as- Equity	Total Net Worth	Retur n on Net Wort h	Profitability Ratio					Assets Turno ver Ratio	Curre nt Ratio
	Indivi dual	Cumul ative	Over all					GPM	PBT	PAT	Net Contr ibutio n	P/V Ratio		
	(Number of times)			(Number of times)		%	%	%	%	%		%		
Initi al				3.00	3.00									
1- 2	1.40	1.40		1.33	1.33	4.97		4.56%	2.78%	1.81%	1230. 73	8.36 %	4.16	1.10
2- 3	1.70	1.54		0.63	0.63	3.29		4.77%	3.16%	2.02%	1274. 01	7.42 %	4.27	1.16
3- 4	2.07	1.71	2.07	0.29	0.29	2.37		4.92%	3.46%	2.20%	1452. 15	7.40 %	4.25	1.23
											1630. 30	7.39 %		
4-5	2.51	1.88		0.11	0.11	1.81		5.01%	3.67%	2.33%	1808. 45	7.37 %	4.17	1.31
5-6	3.01	2.07		0.00	0.00	1.44		5.07%	3.83%	2.42%			4.06	1.47

Project at a Glance

BEP

BEP - Maximum Utilisation Year	5
--------------------------------	---

Cash BEP (% of Installed Capacity)	45.04%
------------------------------------	--------

Total BEP (% of Installed Capacity)	46.60%
-------------------------------------	--------

IRR, PAYBACK and FACR

Internal Rate of Return .. (In %age)	28.59%
--	--------

Payback Period of the Project is (In Years)	2 Years 3 Months
---	------------------

Fixed Assets Coverage Ratio (No. of times)	30.285
--	--------

Major Queries/Questions Answered in the Report?

- 1. What is Active Pharma Ingredients (API) Manufacturing industry ?**
- 2. How has the Active Pharma Ingredients(API) Manufacturing industry performed so far and how will it perform in the coming years ?**
- 3. What is the Project Feasibility of Active Pharma Ingredients (API) Manufacturing Plant ?**
- 4. What are the requirements of Working Capital for setting up Active Pharma Ingredients (API) Manufacturing plant ?**

- 5. What is the structure of the Active Pharma Ingredients (API) Manufacturing Business and who are the key/major players ?**
- 6. What is the total project cost for setting up Active Pharma Ingredients (API) Manufacturing Business?**
- 7. What are the operating costs for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 8. What are the machinery and equipment requirements for setting up Active Pharma Ingredients (API) Manufacturing plant ?**

- 9. Who are the Suppliers and Manufacturers of Plant & Machinery for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 10. What are the requirements of raw material for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 11. Who are the Suppliers and Manufacturers of Raw materials for setting up Active Pharma Ingredients (API) Manufacturing Business?**
- 12. What is the Manufacturing Process of Active Pharma Ingredients (API) ?**

- 13. What is the total size of land required for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 14. What will be the income and expenditures for Active Pharma Ingredients (API) Manufacturing Business?**
- 15. What are the Projected Balance Sheets of Active Pharma Ingredients (API) Manufacturing plant ?**
- 16. What are the requirement of utilities and overheads for setting up Active Pharma Ingredients (API) Manufacturing plant?**
- 17. What is the Built up Area Requirement and cost for setting up Active Pharma Ingredients (API) Manufacturing Business?**

18. What are the Personnel (Manpower) Requirements for setting up Active Pharma Ingredients (API) Manufacturing Business?

19. What are Statistics of Import & Export for Active Pharma Ingredients (API) ?

20. What is the time required to break-even of Active Pharma Ingredients (API) Manufacturing Business?

21. What is the Break-Even Analysis of Active Pharma Ingredients (API) Manufacturing plant?

22. What are the Project financials of Active Pharma Ingredients (API) Manufacturing Business?

- 23. What are the Profitability Ratios of Active Pharma Ingredients (API) Manufacturing Project?**
- 24. What is the Sensitivity Analysis-Price/Volume of Active Pharma Ingredients (API) Manufacturing plant?**
- 25. What are the Projected Pay-Back Period and IRR of Active Pharma Ingredients (API) plant?**
- 26. What is the Process Flow Sheet Diagram of Active Pharma Ingredients (API) Manufacturing project?**

27. What are the Market Opportunities for setting up Active Pharma Ingredients (API) Manufacturing plant?

28. What is the Market Study and Assessment for setting up Active Pharma Ingredients (API) Manufacturing Business?

29. What is the Plant Layout for setting up Active Pharma Ingredients (API) Manufacturing Business?



Table of Contents of the Project Report



1. PROJECT LOCATION

1.1. District Profile & Geotechnical Site Characterization

1.1.1. General

1.1.2. History

1.1.3. Geography

1.1.4. Demographics

1.1.5. Drainage

1.1.6. Climate

1.1.7. Map

1.1.8. Culture & Heritage

1.1.9. Tourist Places

1.1.10. Economy

1.1.11. Industry

1.1.12. Transportation

2. INTRODUCTION

3. MARKET SURVEY

3.1. GLOBAL MARKET

3.1.1. Industry Insights

3.1.2. Key Players in the Global APIs Market

3.1.3. Specialty Medicines

3.2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT

3.2.1. Market Dynamics

3.2.2. Market Regional Analysis

3.2.3. Market Drivers and Key Restraints

3.2.4. Market Studied By Top Companies

3.2.5. Market Trends

3.2.6. Market Segmentation

3.2.7. Market Regional Outlook

3.3. MAJOR FIVE ACTIVE PHARMACEUTICAL INGREDIENTS COMPANIES

3.3.1. Market Dynamics

3.3.2. Market Segmentations

3.3.3. Market Regional Analysis

3.3.4. Global Market Key Players

4. EXPORT & IMPORT: ALL COUNTRIES

4.1. EXPORT: ALL COUNTRIES

- 4.1.1. Amoxycilline and its Salts
- 4.1.2. Azithromycin
- 4.1.3. Para Acetyl Aminophenol (Paracetamol)

4.2. IMPORT: ALL COUNTRIES

- 4.2.1. Amoxycilline and its Salts
- 4.2.2. Azithromycin
- 4.2.3. Para Acetyl Aminophenol (Paracetamol)

5. FINANCIALS & COMPARISON OF MAJOR INDIAN PLAYERS/COMPANIES

- 5.1. ABOUT FINANCIAL STATEMENTS OF CMIE DATABASE
- 5.2. PROFITS & APPROPRIATIONS
- 5.3. TOTAL LIABILITIES
- 5.4. TOTAL ASSETS
- 5.5. NET CASH FLOW FROM OPERATING ACTIVITIES

5.6. SECTION – I

- 5.6.1. Name of Company with Contact Details
- 5.6.2. Name of Director(S)
- 5.6.3. Plant Capacity
- 5.6.4. Location of Plant
- 5.6.5. Credit Ratings
- 5.6.6. Name of Raw Material(S) Consumed with Quantity & Cost

5.7. SECTION - II

- 5.7.1. Assets
- 5.7.2. Cash Flow
- 5.7.3. Cost as % Ge of Sales
- 5.7.4. Forex Transaction
- 5.7.5. Growth in Assets & Liabilities
- 5.7.6. Growth in Income & Expenditure
- 5.7.7. Income & Expenditure
- 5.7.8. Liabilities
- 5.7.9. Liquidity Ratios
- 5.7.10. Profitability Ratio
- 5.7.11. Profits
- 5.7.12. Return Ratios
- 5.7.13. Structure of Assets & Liabilities (%)

5.7.14. Working Capital & Turnover Ratios

6. PARACETAMOL

- 6.1. MEDICAL USES
- 6.2. COMBINATION MEDICATIONS
- 6.3. RAW MATERIAL
- 6.4. MANUFACTURING PROCESS
- 6.5. PROCESS FLOW DIAGRAM
- 6.6. MANUFACTURER IN INDIA

7. AZITHROMYCIN

- 7.1. MEDICAL USES
- 7.2. RAW MATERIAL
- 7.3. MANUFACTURING PROCESS
- 7.4. PROCESS FLOW DIAGRAM

8. AMOXICILLIN TRIHYDRATE

- 8.1. MEDICAL USES
- 8.2. RAW MATERIAL
- 8.3. MANUFACTURING PROCESS
- 8.4. PROCESS FLOW DIAGRAM

9. COMPANY PROFILE OF MAJOR PLAYERS

10. EXPORT & IMPORT STATISTICS OF INDIA

- 10.1. EXPORT STATISTICS ON ACTIVE PHARMA INGREDIENT
- 10.2. IMPORT STATISTICS ON ACTIVE PHARMA INGREDIENT

11. PRESENT MANUFACTURERS

12. BUYER'S LIST

- 12.1. CONTACT DETAILS OF BUYER'S
- 12.2. NAME OF DIRECTOR(S)
- 12.3. PLANT CAPACITY
- 12.4. CREDIT RATINGS
- 12.5. COMPANY WISE CONSUMPTION DETAIL OF THE RAW MATERIALS

13. SUPPLIERS OF PLANT & MACHINERY

14. SUPPLIERS OF RAW MATERIAL

15. PHOTOGRAPHS/IMAGES FOR REFERENCE

- 15.1. MACHINERY PHOTOGRAPHS
- 15.2. RAW MATERIAL PHOTOGRAPHS
- 15.3. PRODUCT PHOTOGRAPHS

16. PLANT LAYOUT

Project Financials

- **Project at a Glance** **Annexure**
 - Assumptions for Profitability workings1
 - Plant Economics.....2
 - Production Schedule.....3
 - Land & Building.....4
- Factory Land & Building
Site Development Expenses

- **Plant & Machinery.....5**
 - Indigenous Machineries**
 - Other Machineries (Miscellaneous, Laboratory etc.)**

- **Other Fixed Assets.....6**
 - Furniture & Fixtures**
 - Pre-operative and Preliminary Expenses**
 - Technical Knowhow**
 - Provision of Contingencies**

- **Working Capital Requirement Per Month.....7**
 - Raw Material**
 - Packing Material**
 - Lab & ETP Chemical Cost**
 - Consumable Store**

- **Overheads Required Per Month and Per Annum.....8**
 Utilities & Overheads (Power, Water and Fuel Expenses etc.)
 Royalty and Other Charges
 Selling and Distribution Expenses
- **Salary and Wages9**
- **Turnover Per Annum10**
- **Share Capital.....11**
 Equity Capital
 Preference Share Capital

- **Annexure 1 :: Cost of Project and Means of Finance**
- **Annexure 2 :: Profitability and Net Cash Accruals**
 - **Revenue/Income/Realisation**
 - **Expenses/Cost of Products/Services/Items**
 - **Gross Profit**
 - **Financial Charges**
 - **Total Cost of Sales**
 - **Net Profit After Taxes**
 - **Net Cash Accruals**

- **Annexure 3 :: Assessment of Working Capital requirements**

- Current Assets
- Gross Working Capital
- Current Liabilities
- Net Working Capital
- Working Note for Calculation of Work-in-process

- **Annexure 4 :: Sources and Disposition of Funds**

- **Annexure 5 :: Projected Balance Sheets**

- ROI (Average of Fixed Assets)
- RONW (Average of Share Capital)
- ROI (Average of Total Assets)

- **Annexure 6 :: Profitability Ratios**

- D.S.C.R
- Earnings Per Share (EPS)
- Debt Equity Ratio

• Annexure 7 :: Break-Even Analysis

- Variable Cost & Expenses
- Semi-Variable/Semi-Fixed Expenses
- Profit Volume Ratio (PVR)
- Fixed Expenses / Cost
- B.E.P

• Annexure 8 to 11 :: Sensitivity Analysis-Price/Volume

- Resultant N.P.B.T
- Resultant D.S.C.R
- Resultant PV Ratio
- Resultant DER
- Resultant ROI
- Resultant BEP

- **Annexure 12 :: Shareholding Pattern and Stake Status**

- **Equity Capital**
- **Preference Share Capital**

- **Annexure 13 :: Quantitative Details-Output/Sales/Stocks**

- **Determined Capacity P.A of Products/Services**
- **Achievable Efficiency/Yield % of Products/Services/Items**
- **Net Usable Load/Capacity of Products/Services/Items**
- **Expected Sales/ Revenue/ Income of Products/ Services/ Items**

- **Annexure 14** :: **Product wise Domestic Sales Realisation**
- **Annexure 15** :: **Total Raw Material Cost**
- **Annexure 16** :: **Raw Material Cost per unit**
- **Annexure 17** :: **Total Lab & ETP Chemical Cost**
- **Annexure 18** :: **Consumables, Store etc.**
- **Annexure 19** :: **Packing Material Cost**
- **Annexure 20** :: **Packing Material Cost Per Unit**

- **Annexure 21 :: Employees Expenses**
- **Annexure 22 :: Fuel Expenses**
- **Annexure 23 :: Power/Electricity Expenses**
- **Annexure 24 :: Royalty & Other Charges**
- **Annexure 25 :: Repairs & Maintenance Expenses**
- **Annexure 26 :: Other Manufacturing Expenses**
- **Annexure 27 :: Administration Expenses**
- **Annexure 28 :: Selling Expenses**

- **Annexure 29 :: Depreciation Charges – as per Books (Total)**
- **Annexure 30 :: Depreciation Charges – as per Books (P & M)**
- **Annexure 31 :: Depreciation Charges - as per IT Act WDV (Total)**
- **Annexure 32 :: Depreciation Charges - as per IT Act WDV (P & M)**
- **Annexure 33 :: Interest and Repayment - Term Loans**
- **Annexure 34 :: Tax on Profits**
- **Annexure 35 :: Projected Pay-Back Period and IRR**

Reasons for Buying our Report:

- **This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, market potential of the product and reasons for investing in the product**
- **This report provides vital information on the product like it's characteristics and segmentation**
- **This report helps you market and place the product correctly by identifying the target customer group of the product**

- **This report helps you understand the viability of the project by disclosing details like machinery required, project costs and snapshot of other project financials**
- **The report provides a glimpse of government regulations applicable on the industry**
- **The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decisions**

Our Approach:

- Our research reports broadly cover Indian markets, present analysis, outlook and forecast for a period of five years.
- The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players
- We use reliable sources of information and databases. And information from such sources is processed by us and included in the report

Scope of the Report

The report titled “Market Survey cum Detailed Techno Economic Feasibility Report on Active Pharma Ingredients.” provides an insight into Active Pharma Ingredients (API) market in India with focus on uses and applications, Manufacturing Process, Process Flow Sheets, Plant Layout and Project Financials of Active Pharma Ingredients (API) project. The report assesses the market sizing and growth of the Indian Active Pharma Ingredients (API) Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line. And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

- **Good Present/Future Demand**
- **Export-Import Market Potential**
- **Raw Material & Manpower Availability**
- **Project Costs and Payback Period**

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in the Active Pharma Ingredients (API) sector in India along with its business prospects. Through this report we have identified Active Pharma Ingredients (API) project as a lucrative investment avenue.

Tags

#Activepharmaingredients #pharmaingredients #IndianPharma
#medicineingredients #paracetamolingredients #amoxicillinTrihydrate
#Azithromycin #COVID19 #Paracetamol #coronavirus
#CoronavirusBusiness #COVID2019 #CaronaBUSINESS
#lockdownbusiness #businessinlockdown #coronavirusbusiness
#Entrepreneurs #covid19business #DetailedProjectReport
#businessconsultant #BusinessPlan #feasibilityReport #NPCS
#industrialproject #entrepreneurindia #startupbusiness
#startupbusinessideas #businessesestostart #startupideas
#startupbusinesswithnomoney #businessstartupindia #API

**Niir Project Consultancy Services (NPCS)
can provide Detailed Project Report on**

**Production of Active Pharma Ingredients
(API) (Amoxicillin Trihydrate,
Azithromycin & Paracetamol).**
**Investment Opportunities in
Pharmaceutical Industry.**

See more
Project Reports & Profiles
BOOKS



www.entrepreneurindia.co

Visit us at

www.entrepreneurindia.co

www.niir.org



www.entrepreneurindia.co

**Take a look at
Niir Project Consultancy Services
on #Street View**

<https://goo.gl/VstWkd>

*Locate us on
Google Maps*

<https://goo.gl/maps/BKkUtg9gevT2>

OUR CLIENTS

Our inexhaustible Client list includes public-sector companies, Corporate Houses, Government undertaking, individual entrepreneurs, NRI, Foreign investors, non-profit organizations and educational institutions from all parts of the World. The list is just a glimpse of our esteemed & satisfied Clients.

Click here to take a look
<https://goo.gl/G3ICjV>



Select and Choose the Right Business Startup for You

(Instant Online Project Identification and Selection)

Finding the right startup business is one of the most popular subject today. Starting a business is no easy endeavor, but the time, effort, and challenges can be worth it if you succeed. To give yourself the best chance to be successful, take your time to carefully find the right business for you. We, at NPCS, endeavor to make business selection a simple and convenient step for any entrepreneur/startup. Our expert team, by capitalizing on its dexterity and decade's long experience in the field, has created a list of profitable ventures for entrepreneurs who wish to diversify or venture. The list so mentioned is updated regularly to give you a regular dose of new emerging opportunities.

Visit: <https://www.entrepreneurindia.co/project-identification>



Download Complete List of Project Reports:

▪ Detailed Project Reports

Visit:- <https://www.entrepreneurindia.co/complete-project-list>

NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our Market Survey cum Detailed Techno Economic Feasibility Report provides an insight of market in India. The report assesses the market sizing and growth of the Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line.



And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

- **Good Present/Future Demand**
- **Export-Import Market Potential**
- **Raw Material & Manpower Availability**
- **Project Costs and Payback Period**

The detailed project report covers all aspect of business, from analyzing the market, confirming availability of various necessities such as Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Production Schedule,



Working Capital Requirement, uses and applications, Plant Layout, Project Financials, Process Flow Sheet, Cost of Project, Projected Balance Sheets, Profitability Ratios, Break Even Analysis. The DPR (Detailed Project Report) is formulated by highly accomplished and experienced consultants and the market research and analysis are supported by a panel of experts and digitalized data bank.

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in India along with its business prospects.....[Read more](http://www.entrepreneurindia.co)



Contact us

NIIR PROJECT CONSULTANCY SERVICES

**106-E, Kamla Nagar, Opp. Spark Mall,
New Delhi-110007, India.**

Email: npcs.ei@gmail.com , info@entrepreneurindia.co

Tel: +91-11-23843955, 23845654, 23845886

Mobile: +91-9097075054, 8800733955

Fax: +91-11-23845886

Website : www.entrepreneurindia.co , www.niir.org

Take a look at NIIR PROJECT CONSULTANCY SERVICES on #StreetView

<https://goo.gl/VstWkd>



Niir PROJECT CONSULTANCY SERVICES

An ISO 9001:2015 Company



www.entrepreneurindia.co

Who are we?

- *One of the leading reliable names in industrial world for providing the most comprehensive technical consulting services*
- *We adopt a systematic approach to provide the strong fundamental support needed for the effective delivery of services to our Clients' in India & abroad*



We at NPCS want to grow with you by providing solutions scale to suit your new operations and help you reduce risk and give a high return on application investments. We have successfully achieved top-notch quality standards with a high level of customer appreciation resulting in long lasting relation and large amount of referral work through technological breakthrough and innovative concepts. A large number of our Indian, Overseas and NRI Clients have appreciated our expertise for excellence which speaks volumes about our commitment and dedication to every client's success.



We bring deep, functional expertise, but are known for our holistic perspective: we capture value across boundaries and between the silos of any organization. We have proven a multiplier effect from optimizing the sum of the parts, not just the individual pieces. We actively encourage a culture of innovation, which facilitates the development of new technologies and ensures a high quality product.



What do we offer?

- *Project Identification*
- *Detailed Project Reports/Pre-feasibility Reports*
- *Market Research Reports*
- *Business Plan*
- *Technology Books and Directory*
- *Industry Trend*
- *Databases on CD-ROM*
- *Laboratory Testing Services*
- *Turnkey Project Consultancy/Solutions*
- *Entrepreneur India (An Industrial Monthly Journal)*

How are we different ?

- *We have two decades long experience in project consultancy and market research field*
- *We empower our customers with the prerequisite know-how to take sound business decisions*
- *We help catalyze business growth by providing distinctive and profound market analysis*
- *We serve a wide array of customers , from individual entrepreneurs to Corporations and Foreign Investors*
- *We use authentic & reliable sources to ensure business precision*



Our Approach

Requirement collection



Thorough analysis of the project



Economic feasibility study of the Project



Market potential survey/research



Report Compilation



Who do we Serve?

- Public-sector Companies
- Corporates
- Government Undertakings
- Individual Entrepreneurs
- NRI's
- Foreign Investors
- Non-profit Organizations, NBFC's
- Educational Institutions
- Embassies & Consulates
- Consultancies
- Industry / trade associations



Sectors We Cover

- Ayurvedic And Herbal Medicines, Herbal Cosmetics
- Alcoholic And Non Alcoholic Beverages, Drinks
- Adhesives, Industrial Adhesive, Sealants, Glues, Gum & Resin
- Activated Carbon & Activated Charcoal
- Aluminium And Aluminium Extrusion Profiles & Sections,
- Bio-fertilizers And Biotechnology
- Breakfast Snacks And Cereal Food
- Bicycle Tyres & Tubes, Bicycle Parts, Bicycle Assembling



Sectors We Cover *Cont...*

- Bamboo And Cane Based Projects
- Building Materials And Construction Projects
- Biodegradable & Bioplastic Based Projects
- Chemicals (Organic And Inorganic)
- Confectionery, Bakery/Baking And Other Food
- Cereal Processing
- Coconut And Coconut Based Products
- Cold Storage For Fruits & Vegetables
- Coal & Coal Byproduct



Sectors We Cover *Cont...*

- Copper & Copper Based Projects
- Dairy/Milk Processing
- Disinfectants, Pesticides, Insecticides, Mosquito Repellents,
- Electrical, Electronic And Computer based Projects
- Essential Oils, Oils & Fats And Allied
- Engineering Goods
- Fibre Glass & Float Glass
- Fast Moving Consumer Goods
- Food, Bakery, Agro Processing



Sectors We Cover *Cont...*

- Fruits & Vegetables Processing
- Ferro Alloys Based Projects
- Fertilizers & Biofertilizers
- Ginger & Ginger Based Projects
- Herbs And Medicinal Cultivation And Jatropha (Biofuel)
- Hotel & Hospitality Projects
- Hospital Based Projects
- Herbal Based Projects
- Inks, Stationery And Export Industries



Sectors We Cover

Cont...

- Infrastructure Projects
- Jute & Jute Based Products
- Leather And Leather Based Projects
- Leisure & Entertainment Based Projects
- Livestock Farming Of Birds & Animals
- Minerals And Minerals
- Maize Processing(Wet Milling) & Maize Based Projects
- Medical Plastics, Disposables Plastic Syringe, Blood Bags
- Organic Farming, Neem Products Etc.



Sectors We Cover *Cont...*

- Paints, Pigments, Varnish & Lacquer
- Paper And Paper Board, Paper Recycling Projects
- Printing Inks
- Packaging Based Projects
- Perfumes, Cosmetics And Flavours
- Power Generation Based Projects & Renewable Energy Based Projects
- Pharmaceuticals And Drugs
- Plantations, Farming And Cultivations
- Plastic Film, Plastic Waste And Plastic Compounds
- Plastic, PVC, PET, HDPE, LDPE Etc.



Sectors We Cover *Cont...*

- Potato And Potato Based Projects
- Printing And Packaging
- Real Estate, Leisure And Hospitality
- Rubber And Rubber Products
- Soaps And Detergents
- Stationary Products
- Spices And Snacks Food
- Steel & Steel Products
- Textile Auxiliary And Chemicals



Sectors We Cover *Cont...*

- Township & Residential Complex
- Textiles And Readymade Garments
- Waste Management & Recycling
- Wood & Wood Products
- Water Industry(Packaged Drinking Water & Mineral Water)
- Wire & Cable



MARKET RESEARCH REPORTS

Objective

- ⌘ To get a detailed scenario of the industry along with its structure and classification
- ⌘ To provide a comprehensive analysis of the industry by covering aspects like:
 - ⌘ Growth drivers of the industry
 - ⌘ Latest market trends
 - ⌘ Insights on regulatory framework
 - ⌘ SWOT Analysis
 - ⌘ Demand-Supply Situation
 - ⌘ Foreign Trade
 - ⌘ Porters 5 Forces Analysis

Objective

- ⌘ To provide forecasts of key parameters which helps to anticipate the industry performance
- ⌘ To help chart growth trajectory of a business by detailing the factors that affect the industry growth
- ⌘ To help an entrepreneur/manager in keeping abreast with the changes in the industry
- ⌘ To evaluate the competitive landscape of the industry by detailing:
 - ⌘ Key players with their market shares
 - ⌘ Financial comparison of present players




Clientele

- ⌘Venturist/Capitalists
- ⌘Entrepreneur/Companies
- ⌘Industry Researchers
- ⌘Investment Funds
- ⌘Foreign Investors, NRI's
- ⌘Project Consultants/Chartered Accountants
- ⌘Banks
- ⌘Corporates

[Click here for list](#)



Data Sources



Scope & Coverage





Our Team

- ⌘ Our research team comprises of experts from various financial fields:
- ⌘ MBA's
- ⌘ Industry Researchers
- ⌘ Financial Planners
- ⌘ Research veterans with decades of experience

Structure of the Report

- 1. Overview
- 2. Market Analysis
 - 2.1 Growth Drivers
 - 2.2 Emerging Trends in the Industry
 - 2.3 Regulatory Framework
 - 2.4 SWOT Analysis
 - 2.5 Herfindahl–Hirschman Index (HHI)
- 3. Market Forecasts
- 4. Key Players

Structure of the Report *Cont*

- ⌘5. Key Financials and Analysis
 - ⌘5.1 Contact Information
 - ⌘5.2 Key Financials
 - ⌘5.3 Financial comparison
- ⌘6. Industry Size & Outlook



**Take a look at NIIR PROJECT CONSULTANCY
SERVICES on #Street View**

<https://goo.gl/VstWkd>

Contact us

NIIR PROJECT CONSULTANCY SERVICES

106-E, Kamla Nagar, Opp. Spark Mall,
New Delhi-110007, India.

Email: npcs.ei@gmail.com , info@entrepreneurindia.co

Tel: +91-11-23843955, 23845654, 23845886

Mobile: +91-9097075054, 8800733955

Fax: +91-11-23845886

Website : www.entrepreneurindia.co , www.niir.org

Take a look at NIIR PROJECT CONSULTANCY SERVICES on #StreetView

<https://goo.gl/VstWkd>



Follow us



➤ <https://www.linkedin.com/company/niir-project-consultancy-services>



➤ <https://www.facebook.com/NIIR.ORG>



➤ <https://www.youtube.com/user/NIIRproject>



➤ https://twitter.com/npcs_in



➤ <https://www.pinterest.com/npcsindia/>



THANK YOU

For more information, visit us at:

www.niir.org

www.entrepreneurindia.co